Coloplast (COLO) AGM 2024 summary

Opening remarks and agenda

• AGM opened with welcome, board and executive introductions, confirmation of lawful convening and quorum with 87.79% of votes represented.

• Agenda included annual report approval, profit distribution, remuneration, board and auditor elections, and other business.

Financial performance review

• Organic revenue growth reached 8%, reported revenue rose 10% to DKK 27,030m, and EBIT margin was 27% before special items.

• Net profit after special items was DKK 5,052m; free cash flow was DKK 1,430m; net interest-bearing debt stood at DKK 21.8 billion.

• Dividend proposed at DKK 22 per share, totaling about DKK 5 billion and a payout ratio of 98%.

• Share price increased from DKK 748 to DKK 1,100 during the fiscal year, with a total return of about 20%.

• Outlook for 2024-2025: organic growth of 8%-9%, EBIT margin before special items at 28%, CapEx at DKK 1.4 billion, and tax rate at 22%.

Board and executive committee updates

• Board and executive leadership team introduced, with new members added to reflect focus on four growth platforms.

• Board members proposed for re-election included Lars Rasmussen, Niels Peter Louis-Hansen, Annette Brüls, Carsten Hellmann, Jette Nygaard-Andersen, and Marianne Wiinholt.

• Executive team led by President & CEO Kristian Villumsen, with key roles in finance, operations, and care divisions.

• Annual evaluation showed strong collaboration and high satisfaction with board competencies.

• Two women added to the executive leadership team, raising gender diversity to 28% at senior level.